ES2254655T3 - Uso terapeutico de anticuerpo anti-mag para el tratamiento de la apoplejia isquemica. - Google Patents

Uso terapeutico de anticuerpo anti-mag para el tratamiento de la apoplejia isquemica.

Info

Publication number
ES2254655T3
ES2254655T3 ES02711034T ES02711034T ES2254655T3 ES 2254655 T3 ES2254655 T3 ES 2254655T3 ES 02711034 T ES02711034 T ES 02711034T ES 02711034 T ES02711034 T ES 02711034T ES 2254655 T3 ES2254655 T3 ES 2254655T3
Authority
ES
Spain
Prior art keywords
antibody
mag
human
immunoglobulin
vol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02711034T
Other languages
English (en)
Spanish (es)
Inventor
Elaine Alison Irving
Mary Vinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2254655T3 publication Critical patent/ES2254655T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
ES02711034T 2001-02-08 2002-02-08 Uso terapeutico de anticuerpo anti-mag para el tratamiento de la apoplejia isquemica. Expired - Lifetime ES2254655T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0103174 2001-02-08
GBGB0103174.9A GB0103174D0 (en) 2001-02-08 2001-02-08 Novel method of treatment

Publications (1)

Publication Number Publication Date
ES2254655T3 true ES2254655T3 (es) 2006-06-16

Family

ID=9908386

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02711034T Expired - Lifetime ES2254655T3 (es) 2001-02-08 2002-02-08 Uso terapeutico de anticuerpo anti-mag para el tratamiento de la apoplejia isquemica.

Country Status (11)

Country Link
US (2) US20040170627A1 (https=)
EP (2) EP1357941B1 (https=)
JP (2) JP5005156B2 (https=)
AT (1) ATE314861T1 (https=)
AU (1) AU2002229928A1 (https=)
CY (1) CY1105549T1 (https=)
DE (1) DE60208534T2 (https=)
DK (1) DK1357941T3 (https=)
ES (1) ES2254655T3 (https=)
GB (1) GB0103174D0 (https=)
WO (1) WO2002062383A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP3211084B1 (en) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA06000176A (es) * 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
WO1997001352A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
EP1047449B1 (en) * 1997-10-28 2003-09-10 The University Of British Columbia Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
IL136114A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
JP2004523538A (ja) 2004-08-05
WO2002062383A2 (en) 2002-08-15
AU2002229928A1 (en) 2002-08-19
CY1105549T1 (el) 2010-07-28
EP1357941A2 (en) 2003-11-05
WO2002062383A3 (en) 2003-04-10
EP1645285A2 (en) 2006-04-12
DK1357941T3 (da) 2006-05-01
DE60208534D1 (de) 2006-03-30
JP2008291031A (ja) 2008-12-04
EP1645285A3 (en) 2010-04-14
GB0103174D0 (en) 2001-03-28
DE60208534T2 (de) 2006-11-30
US20080014195A1 (en) 2008-01-17
EP1357941B1 (en) 2006-01-04
US20040170627A1 (en) 2004-09-02
ATE314861T1 (de) 2006-02-15
JP5005156B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
US8071731B2 (en) Humanised anti-MAG antibody or functional fragment thereof
ES2330444T3 (es) Inmunoglobulinas neutralizantes de nogo-a para el tratamiento de enfermedades neurologicas.
US20080014195A1 (en) Antagonists Of Myelin-Associated Glycoprotein And Their Use In The Treatment And/Or Prevention Of Neurological Diseases
IL298086B1 (en) Bispecific antibodies against plasma kallikrein and factor xii
US8017115B2 (en) Therapeutical use of anti-myelin associated glycoprotein (MAG) antibodies
PT1899377E (pt) Anticorpos humanizados específicos para nogo-a e suas utilizações farmacêuticas
RU2303461C2 (ru) Антитела против миелин-ассоциированного гликопротеина (mag)
HK1077206B (en) Anti-mag humanised antibodies and their uses for treating stroke
ZA200500337B (en) Anty-myelin associated glycoprotein (MAG) antibodies